Hydreight Tech Stock Price, News & Analysis

Hydreight (OTCQB: HYDTF) reported that its platform has exceeded 1.3 million product orders placed as of Dec 18, 2025, achieving its full-year 2025 orders target ahead of schedule. The company says roughly 400 licenses were fully onboarded and drove the bulk of 2025 order volume, while the platform now supports about 2,500 licenses—above its 2025 target of 1,000—with most still in onboarding or early activation.

Hydreight deferred formal 2026 guidance to early 2026 pending visibility on enterprise partnerships, M&A, and late-stage opportunities; management continues to prioritize scaling pharmacy, compliance, and platform capabilities.

Hydreight Technologies (OTC:HYDTF) provided a corporate update after reporting Q3 2025 results, reiterating multi-vertical growth, VSDHOne adoption, and initial 2026 priorities.

Key Q3 metrics: GAAP revenue $10.52M (+132% YoY), topline revenue $12.83M (+110% YoY), Adjusted EBITDA $620K, GAAP net income $362K, cash $18.64M, and adjusted margin 28.21%. VSDHOne recorded ~295,000 product orders in Q3 and ~887,000 orders YTD through Dec 1, 2025, with a 2025 target of ~1.3M orders. Management emphasized nurse network growth, pharmacy volume +72% YoY, compliance infrastructure, and 2026 focus areas: margin discipline, automation, onboarding, and multi-vertical scale.

Hydreight (OTCQB: HYDTF) reported Q3 2025 GAAP revenue of $10.52M, up 132% YoY, and record topline of $12.83M (+110% YoY). The company posted GAAP net income of $361,888 for Q3 vs a loss in Q3 2024 and adjusted EBITDA of $619,752, marking the fourth consecutive profitable quarter. Cash on hand was $18.64M at quarter-end.

Operational highlights include ~295,000 VSDHOne product orders processed in Q3, nurse sign-ups up ~49% Q3 YoY, pharmacy orders +~72% YoY, and a definitive agreement to acquire a 5% stake in Perfect Scripts with option to 40%. The company closed an $11.5M convertible debenture in 2025 and continues VSDHOne platform expansion and integration efforts.

Hydreight Technologies (OTCQB: HYDTF) was ranked No. 77 on the 2025 Deloitte Technology Fast 500™ announced Nov. 20, 2025. The company credited growth to expanding its compliant national telehealth and pharmacy infrastructure and rapid partner onboarding to its VSDHOne direct-to-consumer platform.

Hydreight noted prior recognition including #56 on the 2024 Fast 500 and #9 on Deloitte’s 2024 Technology Fast 50 (Canada). Deloitte reported Fast 500 companies posted three-year revenue growth ranging from 122% to 29,738% with an average growth rate of 1,079%.

Hydreight Technologies (OTCQB: HYDTF) reported a corporate update on Oct 23, 2025 highlighting rapid commercial growth, stronger liquidity, and industry recognition.

Key metrics: ~295,000 VSDHOne product orders processed between July–September 2025; CA$18.7M cash on hand as of Oct 22, 2025 after an oversubscribed CA$11.5M convertible debenture closed Sept 4, 2025. Nurse sign-ups rose ~49% YoY (198 vs. 133) in July–September; pharmacy orders grew ~72% YoY. Company ranked #25 on Deloitte’s 2025 Technology Fast 50 (Canada).

Hydreight Technologies (OTC: HYDTF) held its 2025 Annual General Meeting virtually on September 19, 2025, where shareholders approved all proposed items. Key highlights include the approval of the company's fixed omnibus equity incentive plan, which allows for up to 9,000,000 common shares to be issued through various equity-based incentive awards.

The company reappointed key leadership positions, with Shane Madden continuing as CEO, Joshua Sorin as CFO and Corporate Secretary, and Carey Dillen as Audit Committee Chair. The equity incentive plan remains subject to final TSX Venture Exchange approval.

Hydreight Technologies (OTC: HYDTF), a mobile clinical network with a proprietary telehealth platform, reported exceptional growth in August 2025, processing over 80,000 pharmacy and telehealth product orders, significantly exceeding internal forecasts of 55,000 orders.

Key achievements include 33% year-over-year revenue growth in H1 2025, marking the third consecutive profitable quarter. The company added 528 new nurse licenses (72% YoY increase) and saw pharmacy orders surge 86% year-over-year from January to August 2025.

Strategic developments include closing an oversubscribed $11.5M convertible debenture financing, acquiring a 5% stake in Perfect Scripts LLC (with option to increase to 40%), and pursuing AI integration through the planned acquisition of Dynamic IV Therapy Support AI Agent.

Hydreight Technologies (OTC: HYDTF), a nationwide digital healthcare solutions provider, has successfully closed its oversubscribed private placement of unsecured convertible debentures, raising C$11.5 million including the full exercise of the over-allotment option.

The debentures, issued at C$1,000 each, will mature on September 4, 2028, carrying a 9.0% annual interest rate. They are convertible into common shares at C$4.06 per share, with interest payable semi-annually. The company maintains a forced conversion right if the stock trades above C$5.08 for 20 consecutive trading days.

CEO Shane Madden highlighted the company's recent achievement of profitability in Q2 and plans to use the proceeds for general corporate and working capital purposes to accelerate growth.

Hydreight Technologies (OTCQB:HYDTF), a mobile clinical network and medical platform, reported strong financial results for Q2 2025, marking its third consecutive quarter of profitability. The company achieved Q2 GAAP revenue of $5.38 million, up 31% year-over-year, and H1 2025 revenue of $9.92 million, representing a 33% increase.

Key performance metrics include Q2 Gross Margin of $1.93 million, Adjusted EBITDA of $182K, and GAAP Net Income of $50K. The company saw significant growth with a 77% increase in new nurse signups and 48% growth in pharmacy orders compared to Q2 2024.

Hydreight announced a strategic initiative to acquire a 5% equity stake in Perfect Scripts, LLC with an option to increase to 40%, and launched a C$10 Million Convertible Debenture Offering to support growth and M&A activities.